Table 1.
In vitro kinase inhibition profile of anlotinib
| Kinase | IC50 (nmol/L, mean ± SD) | |
|---|---|---|
| Anlotinib | Sunitinib | |
| VEGFR2 | 0.2 ± 0.1 | 4.0 ± 2.9 |
| c‐Kit | 14.8 ± 2.5 | 11.0 ± 1.5 |
| PDGFRβ | 115.0 ± 62.0 | 7.7 ± 2.2 |
| VEGFR1 | 26.9 ± 7.7 | 71.5 ± 12.8 |
| VEGFR3 | 0.7 ± 0.1 | 15.7 ± 2.1 |
| c‐Met | >2000 | >2000 |
| c‐Src | >2000 | >2000 |
| HER2 | >2000 | >2000 |
| EGFR | >2000 | >2000 |
Potency of anlotinib against recombinant tyrosine kinases in vitro, expressed as IC50. Values are presented as mean ± SD (n = 3).
EGFR, epidermal growth factor receptor; PDGFRβ, platelet‐derived growth factor receptor β; VEGFR1, vascular endothelial growth factor receptor‐1; VEGFR2, vascular endothelial growth factor receptor‐2; VEGFR3, vascular endothelial growth factor receptor‐3.